468 related articles for article (PubMed ID: 24519384)
41. Ursodeoxycholic acid for primary sclerosing cholangitis.
Chazouillères O; Poupon R; Capron JP; Metman EH; Dhumeaux D; Amouretti M; Couzigou P; Labayle D; Trinchet JC
J Hepatol; 1990 Jul; 11(1):120-3. PubMed ID: 1975818
[TBL] [Abstract][Full Text] [Related]
42. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
43. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
44. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
[TBL] [Abstract][Full Text] [Related]
45. Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study.
Manna LB; Ovadia C; Lövgren-Sandblom A; Chambers J; Begum S; Seed P; Walker I; Chappell LC; Marschall HU; Williamson C
BJOG; 2019 Dec; 126(13):1633-1640. PubMed ID: 31483939
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
47. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.
Xiang X; Vakkilainen J; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2011 Nov; 67(11):1159-67. PubMed ID: 21655991
[TBL] [Abstract][Full Text] [Related]
48. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study.
Trottier J; Białek A; Caron P; Straka RJ; Heathcote J; Milkiewicz P; Barbier O
Dig Liver Dis; 2012 Apr; 44(4):303-10. PubMed ID: 22169272
[TBL] [Abstract][Full Text] [Related]
49. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
50. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
[TBL] [Abstract][Full Text] [Related]
51. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
52. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice.
Treeprasertsuk S; Silachamroon U; Krudsood S; Huntrup A; Suwannakudt P; Vannaphan S; Wilairatana P
J Gastroenterol Hepatol; 2010 Feb; 25(2):362-8. PubMed ID: 19817958
[TBL] [Abstract][Full Text] [Related]
53. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
[TBL] [Abstract][Full Text] [Related]
54. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
[TBL] [Abstract][Full Text] [Related]
55. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
56. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease.
Kneppelhout JC; Mulder CJ; van Berge Henegouwen GP; de Vries RA; Brandt KH
Neth J Med; 1992 Aug; 41(1-2):11-6. PubMed ID: 1407234
[TBL] [Abstract][Full Text] [Related]
57. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.
Zhu GQ; Shi KQ; Huang GQ; Wang LR; Lin YQ; Braddock M; Chen YP; Zhou MT; Zheng MH
Oncotarget; 2015 Sep; 6(29):26757-69. PubMed ID: 26378046
[TBL] [Abstract][Full Text] [Related]
58. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
59. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
60. Bile acids for primary sclerosing cholangitis.
Poropat G; Giljaca V; Stimac D; Gluud C
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
